[go: up one dir, main page]

WO2023217170A1 - Utilisation d'un inhibiteur de btk pour le traitement d'une maladie - Google Patents

Utilisation d'un inhibiteur de btk pour le traitement d'une maladie Download PDF

Info

Publication number
WO2023217170A1
WO2023217170A1 PCT/CN2023/093180 CN2023093180W WO2023217170A1 WO 2023217170 A1 WO2023217170 A1 WO 2023217170A1 CN 2023093180 W CN2023093180 W CN 2023093180W WO 2023217170 A1 WO2023217170 A1 WO 2023217170A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
btk inhibitor
inhibitor
mice
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/093180
Other languages
English (en)
Chinese (zh)
Inventor
吴奕涵
王敏
丁珊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reistone Biopharma Co Ltd
Original Assignee
Reistone Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reistone Biopharma Co Ltd filed Critical Reistone Biopharma Co Ltd
Priority to CN202380040477.XA priority Critical patent/CN119365197A/zh
Publication of WO2023217170A1 publication Critical patent/WO2023217170A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the JAK inhibitor and the BTK inhibitor are administered simultaneously or sequentially, and the time interval of administration is limited to the extent that a synergistic effect can be achieved, and the time interval of administration can be determined by a skilled person.
  • a subject is an individual diagnosed with, suspected of having, or susceptible to the disease or condition.
  • the frequency of administration of the BTK inhibitor of the present disclosure can be once a day, twice a day, three times a day, once every two days, once every three days, once a week, etc.
  • This experiment uses a urea nitrogen (BUN) test kit to detect the content of urea nitrogen in mouse serum.
  • the experimental steps are as follows: (1) Take 10 ⁇ L double-distilled water as the blank control, 10 mmol/L BUN standard application solution as the standard sample, and add 10 ⁇ L serum of each group of mice into a 1.5 mL EP tube, and then add 125 ⁇ L buffer enzyme solution ; (2) After mixing, take a 37°C water bath for 10 minutes; (3) Add 500 ⁇ L of phenol chromogen and 500 ⁇ L of alkaline sodium hypochlorite to each sample in turn, mix thoroughly, and keep in a 37°C water bath for 10 minutes.
  • BUN urea nitrogen
  • the anti-dsDNA IgG content in the kidneys of mice in the 2.5 mg/kg Compound B (BID) + 1.5 mg/kg Compound A (QD) combination group was significantly lower than that in the blank group (P ⁇ 0.001); and the corresponding doses of Compound B or Compared with the compound A single drug group, the anti-dsDNA IgG content in the kidneys of mice in the combination group was significantly reduced (P ⁇ 0.05), indicating that 2.5 mg/kg compound B (BID) and 1.5 mg/kg compound A (QD) were used in combination , has a significant synergistic improvement effect on the deposition of anti-dsDNA IgG in the kidney.
  • the estimated eGFR during screening (calculated using the CKD-EPI formula) is ⁇ 60mL/min/1.73m 2 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation d'un inhibiteur de BTK pour le traitement d'une maladie. Spécifiquement, la présente invention concerne l'utilisation de l'inhibiteur de BTK dans la préparation d'un médicament pour prévenir ou traiter une néphropathie membraneuse, une protéinurie, une néphropathie lupique ou une lésion rénale lupique.
PCT/CN2023/093180 2022-05-10 2023-05-10 Utilisation d'un inhibiteur de btk pour le traitement d'une maladie Ceased WO2023217170A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202380040477.XA CN119365197A (zh) 2022-05-10 2023-05-10 Btk抑制剂用于治疗疾病的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210532478.3 2022-05-10
CN202210532478 2022-05-10

Publications (1)

Publication Number Publication Date
WO2023217170A1 true WO2023217170A1 (fr) 2023-11-16

Family

ID=88729722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/093180 Ceased WO2023217170A1 (fr) 2022-05-10 2023-05-10 Utilisation d'un inhibiteur de btk pour le traitement d'une maladie

Country Status (3)

Country Link
CN (1) CN119365197A (fr)
TW (1) TW202408524A (fr)
WO (1) WO2023217170A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088315A1 (fr) * 2022-10-26 2024-05-02 Beigene, Ltd. Méthodes de traitement d'une néphropathie membraneuse primaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128912A1 (fr) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1, et/ou d'un inhibiteur de pd-l1
WO2021141919A1 (fr) * 2020-01-06 2021-07-15 Principia Biopharma Inc. Traitement d'une néphropathie membraneuse, d'une maladie liée à igg4 et d'un syndrome d'antiphospholipides à l'aide d'un inhibiteur de btk 2-[(3r)-3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidin-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétan-3-yl)pipérazin-1-yl]pent-2-ènenitrile
WO2022033460A1 (fr) * 2020-08-10 2022-02-17 江苏恒瑞医药股份有限公司 Utilisation d'inhibiteurs de btk dans le traitement de maladies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128912A1 (fr) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1, et/ou d'un inhibiteur de pd-l1
WO2021141919A1 (fr) * 2020-01-06 2021-07-15 Principia Biopharma Inc. Traitement d'une néphropathie membraneuse, d'une maladie liée à igg4 et d'un syndrome d'antiphospholipides à l'aide d'un inhibiteur de btk 2-[(3r)-3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidin-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétan-3-yl)pipérazin-1-yl]pent-2-ènenitrile
WO2022033460A1 (fr) * 2020-08-10 2022-02-17 江苏恒瑞医药股份有限公司 Utilisation d'inhibiteurs de btk dans le traitement de maladies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. A. HONIGBERG, A. M. SMITH, M. SIRISAWAD, E. VERNER, D. LOURY, B. CHANG, S. LI, Z. PAN, D. H. THAMM, R. A. MILLER, J. J. BUGGY: "The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 29, 20 July 2010 (2010-07-20), pages 13075 - 13080, XP055216525, ISSN: 00278424, DOI: 10.1073/pnas.1004594107 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088315A1 (fr) * 2022-10-26 2024-05-02 Beigene, Ltd. Méthodes de traitement d'une néphropathie membraneuse primaire

Also Published As

Publication number Publication date
CN119365197A (zh) 2025-01-24
TW202408524A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
AU2020222296B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
US20220152026A1 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
US20100278824A1 (en) Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
AU2013299841A1 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
TW202302095A (zh) 使用ｂｅｔ抑制劑治療骨髓纖維化
CN111093706A (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
WO2023217170A1 (fr) Utilisation d'un inhibiteur de btk pour le traitement d'une maladie
CN115701997B (zh) Btk抑制剂治疗疾病的用途
US20240374601A1 (en) Methods and compositions for treating cancer
TW202144409A (zh) 抗vegf抗體和抗pd-1抗體組合用於預防或治療疾病的應用
CN118678960A (zh) 用于治疗癌症的方法和组合物
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
JP2025536290A (ja) Ｗｎｔ経路腫瘍抑制因子に突然変異を有する癌の治療
CN108883106A (zh) 使用了乐伐替尼和依维莫司的肾细胞癌治疗
WO2012060308A1 (fr) Médicament pour la prévention et le traitement de dysfonctionnement rénal
WO2023030437A1 (fr) Utilisation d'un inhibiteur de pi3k et d'un inhibiteur de btk dans la préparation d'un médicament pour le traitement d'un lymphome
US20170312234A1 (en) Pharmaceutical composition and use thereof
WO2025157254A1 (fr) Composition pharmaceutique de composé contenant un groupe sulfonyle, et son utilisation
WO2025242126A1 (fr) Composition pharmaceutique et utilisation associée
CN118019537A (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
CN117615759A (zh) Bet抑制剂单独或者与菲卓替尼或芦可替尼组合用于治疗血液恶性肿瘤如骨髓纤维化的用途
EA046794B1 (ru) Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
HK40025353A (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23802939

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380040477.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202380040477.X

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 23802939

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 23802939

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23.05.2025)